Advances in the management of Anderson–Fabry disease:enzyme replacement therapy

Bibliography

• BRADY RO, GAL AE, BRADLEY RM, MARTENSSON E, WARSHAW AL, LASTER L: Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. (1967) 276(21):1163–1167.
   PubMed Web of Science ®Google Scholar
• DESNICK RJ, IOANNOU YA, ENG CM: a-Galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Basis of Inherited disease. 8th Edition. Volume 3. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.) McGraw Hill, New York, USA (2001):3733–3774.
   Google Scholar
• PETERS FP, SOMMER A, VERMEULEN A, CHERIEX EC, KHO TL: Fabry's disease: a multidisciplinary disorder. Postgrad. Med. J. (1997) 73(865):710–712.
   PubMed Web of Science ®Google Scholar
• MACDERMOT J, MACDERMOT KD: Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur.j Pharmacol (2001) 429(1-3):121–125.
   PubMed Web of Science ®Google Scholar
• WENDRICH K, WHYBRA C, RIES M, GAL A, BECK M: Neurological manifestation of Fabry disease in females. Contrib. Nephrol (2001) 136:241–244.
   PubMed Web of Science ®Google Scholar
• WHYBRA C, WENDRICH K, RIES M, GAL A, BECK M: Clinical manifestation in female Fabry disease patients. Contrib. Nephrol (2001) 136:245–250.
   PubMed Web of Science ®Google Scholar
• MACDERMOT KD, HOLMES A, MINERS AH: Anderson-Fabry Disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet. (2001) 38:750–760.
   PubMed Web of Science ®Google Scholar
• MACDERMOT KD, HOLMES A, MINERS AH: Anderson-Fabry Disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet. (2001) 38:769–807.
   PubMed Web of Science ®Google Scholar
• MEIKLE PJ, HOP WOOD JJ, CLAGUE AE, CAREY WF: Prevalence of lysosomal storage disorders. JAMA (1999) 281:249–254.
   PubMed Web of Science ®Google Scholar
• NAKAO S, TAKENAKA T, MAEDA M et al.: An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl. J. Med. (1995) 333:288–293.
   PubMed Web of Science ®Google Scholar
• KUHN H, KOHLER E, HORT W, FRENZEL H: Concealed myocardial storage disease (Fabry's disease): pitfalls in the diagnosis of hypertrophic nonobstructive cardiomyopathy. Circulation (1982) 66\(Suppl. 2):117. Abstract.
   Google Scholar
• BRADY RO: Gaucher's disease: past, present and future. Baillieres. Clin. Haematol. (1997) 10(4):621–634.
   PubMedGoogle Scholar
• COX TM: Gaucher's disease-an exemplary monogenic disorder. QJM(2001) 94(8):399–402.
   PubMed Web of Science ®Google Scholar
• ELSTEIN D, ABRAHAMOV A, HADAS-HALPERN I, ZIMRAN A: Gaucher's disease. Lancet (2001) 358(9278):324–327.
   PubMed Web of Science ®Google Scholar
• PASTORES GM. Gaucher disease and its treatment: lessons learned and future perspectives. In: Enlermedad de Gaucher: Epidemiologia, Clinica, Diagnostic° y 7erapeutica. Giraldo MP, Giralt M, Perez-Calvo JI, Pocovi M (Eds.) Imprenta Ibarguen, SC, Zaragoza, Spain (1999):13–17.
   Google Scholar
• OHSHIMA T, MURRAY GJ, SWAIM WD et al.: Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Li. USA (1997) 94(6):2540–2544.
   PubMed Web of Science ®Google Scholar
• WANG AM, IOANNOU YA, ZEIDNER KM et al.: Generation of a mouse model with a-galactosidase A deficiency. Am. J. Hum. Genet. (1996) 59:A208.
   Google Scholar
• IOANNOU YA, ZEIDNER KM, GORDON RE, DESNICK RJ: Fabry disease: preclinical studies demonstrate the effectiveness of a-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. (2001) 68(1):14–25.
   PubMed Web of Science ®Google Scholar
• BRADY RO, MURRAY GJ, MOORE DF, SCHIFFMANN R: Enzyme replacement therapy in Fabry disease. J. Inherit. Metab. Dis. (2001) 24\(Suppl. 2):18–24.
   Google Scholar
• SCHIFFMANN R, MURRAY GJ, TRECO D et al.: Infusion of a-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. ScL USA (2000) 97(1):365–370.
   PubMed Web of Science ®Google Scholar
• SCHIFFMANN R, KOPP JB, AUSTIN HA III et al.: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA (2001) 285:2743–2749.
   Google Scholar
• ENG CM, BANIKAZEMI M, GORDON RE et al.: A Phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. (2001) 68:711–722.
   PubMed Web of Science ®Google Scholar
• ENG CM, GUFFON N, WILCOX WR et al.: Safety and efficacy of recombinant human a-galactosidase A replacement in Fabry disease. N Engl. J. Med. (2001) 345:9–16.
   PubMed Web of Science ®Google Scholar
• MACDERMOT K, BROWN A, JONES Y, ZUCKERMAN J: Enzyme replacement therapy reverses the cardiomyopathy of Fabry disease: results of a randomized, double-blind, placebo-controlled trial. Euro. J. Hum. Genet. (2001):92. Abstract C074.
   Google Scholar
• DESNICK RJ: Reported at the 39th AnnualSymposium of the Society for the Study of Inborn Errors of Metabolism, Prague, Czech Republic (2001) and the 51st Amnia] Meeting of the Society of Human Genetics, San Diego, California (2001). Abstract #2895.
   Google Scholar
• SCHIFFMANN R, KOPP JB, MOORE DF, WEIBEL T, CHARRIA G, BRADY RO: Efficacy and safety of prolonged enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. (2001) 69(4) (Suppl.):222.
   Google Scholar
• MOORE DF, HERSCOVITCH P, SCHIFFMANN R: Selective arterial distribution of cerebral hyperperfusion in Fabry disease. j Neuraimaging (2001) 11(3):303–307.
   PubMed Web of Science ®Google Scholar
• MOORE DF, SCOTT LT, GLADWIN MT et al.: Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation (2001) 104(13):1506–1512.
   PubMed Web of Science ®Google Scholar
• MOORE DF, ALTARESCU A, LING GSF et al.: Cerebrovascular hyperdynamicity in Fabry disease with reversal following enzyme replacement therapy. Stroke (2002). In press.
   Google Scholar
• ALTARESCU G, MOORE DE PURSLEY R et al.: Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke (2001) 32(7):1559–1562.
   Google Scholar
• DEGRABA T, AZHAR S, DIGNAT-GEORGE F et al.: Profile of endothelial and leukocyte activation in Fabry patients. Ann. Neural (2000) 47(2):229–233.
   PubMed Web of Science ®Google Scholar
• ALTARESCU GM, GOLDFARB LG, PARK KY et al: Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Chu. Genet. (2001) 60(1):46–51.
   PubMed Web of Science ®Google Scholar
• BLAYDON D, HILL J, WINCHESTERB: Fabry disease: 20 novel GLA mutations in 35 families. Hum. MutaL (2001) 18(5):459.
   PubMedGoogle Scholar
• BRANTON MH, SCHIFFMANN R, SABNIS SG et al.: Quantitative natural history of Fabry renal disease: influence of ot-galactosidase A activity and genetic mutations on clinical course. Medicine (2002). In press.
   Google Scholar
• MACDERMOT J, MACDERMOT KD: Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur. Pharmacy]. (2001) 429(1-3):121–125.
   PubMed Web of Science ®Google Scholar
• MINERS AH, HOLMES A, MACDERMOT KD: Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual. Life (2002). In press.
   Google Scholar
• Honorable Gregory M Sleet (US District Court of Delaware), in December 2001, informed the parties he will dismiss the patent litigation Genzyme Corporation and Mount Sinai School of Medicine brought against TKT; claims of infringement related to US Patent No. 5,356,804.
   Google Scholar
• VANCE DE, KRIVIT W, SWEELEY CC: Metabolism of neutral glycosphingolipids in plasma of a normal human and a patient with Fabry's disease. j Biol. Chem. (1975) 250(20):8119–8125.
   PubMed Web of Science ®Google Scholar
• BEUTLER E, WESTWOOD B, DALE GL: The effect of phlebotomy as a treatment of Fabry disease. Biochem. Med (1983) 30(3):363–368.
   PubMedGoogle Scholar
• BRAINE HG, PYERITZ RE, FOLSTEIN ME MOSER HB, ULLMAN MD: A prospective double-blind study of plasma exchange therapy for the acroparesthesia of Fabry's disease. Transfusion (1981) 21(6):686–689.
   PubMedGoogle Scholar
• PYERITZ RE, ULLMAN MD, MOSER AB, BRAINE HG, MOSER HW: Plasma exchange removes glycosphingolipid in Fabry disease. Am. j Med. Genet. (1980) 7(3):301–307.
   PubMed Web of Science ®Google Scholar
• CHATTERJEE S, GUPTA P, PYERITZ RE, KWITEROVICH PO JR.: Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry's disease. Am. j Chu. Pathal (1984) 82(1):24–28.
   Google Scholar
• PASTORES GM, THADHANI R: Enzyme-replacement therapy for Anderson-Fabry disease. Lancet (2001) 358(9282):601–603.
   PubMed Web of Science ®Google Scholar
• ABE A, GREGORY S, LEE L et al.: Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. Chu. Invest. (2000) 105:1563–1571.
   PubMed Web of Science ®Google Scholar
• FRUSTACI A, CHIMENTI C, RICCI R et al.: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl. j Med. (2001) 345:25–32.
   PubMed Web of Science ®Google Scholar
• JUNG SC, HAN IP, LIMAYE A et al: Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc. Natl. Acad. ScL USA (2001) 98:2676–2681.
   PubMed Web of Science ®Google Scholar